Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle AM, Abebo TA, Abera SF, Aboyans V (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2017). Lancet 390(10100):1211–1259. https://doi.org/10.1016/s0140-6736(17)32154-2

Article  Google Scholar 

Cuijpers I, Simmonds SJ, van Bilsen M, Czarnowska E, González Miqueo A, Heymans S, Kuhn AR, Mulder P, Ratajska A, Jones EAV, Brakenhielm E (2020) Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Res Cardiol 115(4):39. https://doi.org/10.1007/s00395-020-0798-y

Article  PubMed  PubMed Central  Google Scholar 

Goligorsky MS (2010) Microvascular rarefaction: the decline and fall of blood vessels. Organogenesis 6(1):1–10. https://doi.org/10.4161/org.6.1.10427

Article  PubMed  PubMed Central  Google Scholar 

Wong BW, Marsch E, Treps L, Baes M, Carmeliet P (2017) Endothelial cell metabolism in health and disease: impact of hypoxia. EMBO J 36(15):2187–2203. https://doi.org/10.15252/embj.201696150

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singhal AK, Symons JD, Boudina S, Jaishy B, Shiu YT (2010) Role of endothelial cells in myocardial ischemia-reperfusion injury. Vasc Dis Prev 7:1–14. https://doi.org/10.2174/1874120701007010001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basile DP (2004) Rarefaction of peritubular capillaries following ischemic acute renal failure: a potential factor predisposing to progressive nephropathy. Curr Opin Nephrol Hypertens 13(1):1–7. https://doi.org/10.1097/00041552-200401000-00001

Article  PubMed  Google Scholar 

Hinkel R, Howe A, Renner S, Ng J, Lee S, Klett K, Kaczmarek V, Moretti A, Laugwitz KL, Skroblin P, Mayr M, Milting H, Dendorfer A, Reichart B, Wolf E, Kupatt C (2017) Diabetes mellitus-induced microvascular destabilization in the myocardium. J Am Coll Cardiol 69(2):131–143. https://doi.org/10.1016/j.jacc.2016.10.058

Article  CAS  PubMed  Google Scholar 

Yeung L, Wu IW, Sun CC, Liu CF, Chen SY, Tseng CH, Lee HC, Lee CC (2019) Early retinal microvascular abnormalities in patients with chronic kidney disease. Microcirculation. https://doi.org/10.1111/micc.12555

Article  PubMed  PubMed Central  Google Scholar 

Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC (2013) Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 6(6):660–667. https://doi.org/10.1016/j.jcmg.2012.12.011

Article  PubMed  Google Scholar 

Kakuta K, Dohi K, Sato Y, Yamanaka T, Kawamura M, Ogura T, Nakamori S, Fujimoto N, Fujii E, Yamada N, Ito M (2016) Chronic inflammatory disease is an independent risk factor for coronary flow velocity reserve impairment unrelated to the processes of coronary artery calcium deposition. J Am Soc Echocardiogr 29(2):173–180. https://doi.org/10.1016/j.echo.2015.09.001

Article  PubMed  Google Scholar 

Brevetti G, Giugliano G, Brevetti L, Hiatt WR (2010) Inflammation in peripheral artery disease. Circulation 122(18):1862–1875. https://doi.org/10.1161/CIRCULATIONAHA.109.918417

Article  PubMed  Google Scholar 

Ruparelia N, Chai JT, Fisher EA, Choudhury RP (2017) Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol 14(3):133–144. https://doi.org/10.1038/nrcardio.2016.185

Article  CAS  PubMed  Google Scholar 

Martínez-Hervás S, González-Navarro H (2019) Anti-inflammatory therapies for cardiovascular disease: signaling pathways and mechanisms. Rev Esp Cardiol 72(9):767–773. https://doi.org/10.1016/j.rec.2019.03.007

Article  PubMed  Google Scholar 

Ma J, Chen X (2021) Anti-inflammatory therapy for coronary atherosclerotic heart disease: unanswered questions behind existing successes. Front Cardiovasc Med. https://doi.org/10.3389/fcvm.2020.631398

Article  PubMed  PubMed Central  Google Scholar 

Ueland T, Aukrust P, Aakhus S, Smith C, Endresen K, Birkeland KI, Gullestad L, Johansen OE (2012) Activin A and cardiovascular disease in type 2 diabetes mellitus. Diab Vasc Dis Res 9(3):234–237. https://doi.org/10.1177/1479164111431171

Article  PubMed  Google Scholar 

Yndestad A, Ueland T, Oie E, Florholmen G, Halvorsen B, Attramadal H, Simonsen S, Froland SS, Gullestad L, Christensen G, Damas JK, Aukrust P (2004) Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 109(11):1379–1385. https://doi.org/10.1161/01.CIR.0000120704.97934.41

Article  CAS  PubMed  Google Scholar 

Miyoshi T, Hirohata S, Uesugi T, Hirota M, Ohnishi H, Nogami K, Hatanaka K, Ogawa H, Usui S, Kusachi S (2009) Relationship between activin A level and infarct size in patients with acute myocardial infarction undergoing successful primary coronary intervention. Clin Chim Acta 401(1–2):3–7. https://doi.org/10.1016/j.cca.2008.10.027

Article  CAS  PubMed  Google Scholar 

Jones KL, Brauman JN, Groome NP, de Kretser DM, Phillips DJ (2000) Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 141(5):1905–1908. https://doi.org/10.1210/endo.141.5.7531

Article  CAS  PubMed  Google Scholar 

Takahashi S, Nakasatomi M, Takei Y, Ikeuchi H, Sakairi T, Kaneko Y, Hiromura K, Nojima Y, Maeshima A (2018) Identification of urinary activin A as a novel biomarker reflecting the severity of acute kidney injury. Sci Rep 8(1):5176. https://doi.org/10.1038/s41598-018-23564-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zou L, Liu J, Lu H (2018) Correlation of concentrations of activin A with occurrence and severity of knee osteoarthritis. J Musculoskelet Neuronal Interact 18(3):320–322

CAS  PubMed  PubMed Central  Google Scholar 

Zhou G, Gui X, Chen R, Fu X, Ji X, Ding H (2019) Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting. Clinics. https://doi.org/10.6061/clinics/2019/e981

Article  PubMed  PubMed Central  Google Scholar 

Lin JF, Hsu SY, Teng MS, Wu S, Hsieh CA, Jang SJ, Liu CJ, Huang HL, Ko YL (2016) Activin A predicts left ventricular remodeling and mortality in patients with ST-elevation myocardial infarction. Acta Cardiol Sin 32(4):420–427. https://doi.org/10.6515/acs20150415a

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wei Q, Wang YN, Liu HY, Yang J, Yang CY, Liu M, Liu YF, Yang P, Liu ZH (2013) The expression and role of activin A and follistatin in heart failure rats after myocardial infarction. Int J Cardiol 168(3):2994–2997. https://doi.org/10.1016/j.ijcard.2013.04.012

Article  PubMed  Google Scholar 

Chen WJ, Greulich S, van der Meer RW, Rijzewijk LJ, Lamb HJ, de Roos A, Smit JW, Romijn JA, Ruige JB, Lammertsma AA, Lubberink M, Diamant M, Ouwens DM (2013) Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes. Cardiovasc Diabetol 12:150. https://doi.org/10.1186/1475-2840-12-150

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fukushima N, Matsuura K, Akazawa H, Honda A, Nagai T, Takahashi T, Seki A, Murasaki KM, Shimizu T, Okano T, Hagiwara N, Komuro I (2011) A crucial role of activin A-mediated growth hormone suppression in mouse and human heart failure. PLoS ONE 6(12):e27901. https://doi.org/10.1371/journal.pone.0027901

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masutani S (2019) Activin A- a potentially useful biomarker of diastolic dysfunction. Circ J 83(7):1443–1445. https://doi.org/10.1253/circj.CJ-19-0449

Article  CAS  PubMed  Google Scholar 

Agapova OA, Fang Y, Sugatani T, Seifert ME, Hruska KA (2016) Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int 89(6):1231–1243. https://doi.org/10.1016/j.kint.2016.02.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bian X, Griffin TP, Zhu X, Islam MN, Conley SM, Eirin A, Tang H, O’Shea PM, Palmer AK, McCoy RG, Herrmann SM, Mehta RA, Woollard JR, Rule AD, Kirkland JL, Tchkonia T, Textor SC, Griffin MD, Lerman LO, Hickson LJ (2019) Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy. BMJ Open Diabetes Res Care 7(1):e000720. https://doi.org/10.1136/bmjdrc-2019-000720

Article  PubMed  PubMed Central  Google Scholar 

Maeshima A, Zhang YQ, Nojima Y, Naruse T, Kojima I (2001) Involvement of the activin-follistatin system in tubular regeneration after renal ischemia in rats. J Am Soc Nephrol 12(8):1685–1695

Article  CAS  PubMed  Google Scholar 

Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL (1997) Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 349(9061):1285–1288. https://doi.org/10.1016/s0140-6736(96)09264-1

Article  CAS  PubMed  Google Scholar 

Su X, Huang L, Xiao D, Qu Y, Mu D (2018) Research progress on the role and mechanism of action of Activin A in brain injury. Front Neurosci 12:697. https://doi.org/10.3389/fnins.2018.00697

Article  PubMed  PubMed Central  Google Scholar 

Florio P, Gazzolo D, Luisi S, Petraglia F (2007) Activin A in brain injury. Adv Clin Chem 43:117–130. https://doi.org/10.1016/s0065-2423(06)43004-3

Article  CAS  PubMed  Google Scholar 

Leonhard WN, Kunnen SJ, Plugge AJ, Pasternack A, Jianu SBT, Veraar K, el Bouazzaoui F, Hoogaars WMH, ten Dijke P, Breuning MH, De Heer E, Ritvos O, Peters DJM (2016) Inhibition of activin signaling slows progression of polycystic kidney disease. J Am Soc Nephrol 27(12):3589–3599. https://doi.org/10.1681/asn.2015030287

Article  CAS